VitaSpring Biomedical Co. Ltd.
VSBC
$0.01
-$0.24-95.56%
OTC PK
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -129.93% | -128.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -129.93% | -128.77% |
| Cost of Revenue | -- | -- | -- | -18.22% | -22.92% |
| Gross Profit | -- | -- | -- | -292.07% | -290.20% |
| SG&A Expenses | -18.82% | 11.50% | 32.41% | 35.48% | 33.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -74.51% | -69.10% | -73.23% | -6.27% | -11.23% |
| Operating Income | 82.10% | 78.64% | 73.23% | -530.66% | -510.28% |
| Income Before Tax | 82.10% | 78.64% | 73.17% | -527.96% | -507.62% |
| Income Tax Expenses | -- | -- | -- | -101.83% | -117.18% |
| Earnings from Continuing Operations | 81.92% | 78.28% | 73.14% | -639.90% | -629.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 81.92% | 78.28% | 73.14% | -639.90% | -629.11% |
| EBIT | 82.10% | 78.64% | 73.23% | -530.66% | -510.28% |
| EBITDA | 82.30% | 78.86% | 73.49% | -523.96% | -504.05% |
| EPS Basic | 82.08% | 78.70% | 73.27% | -642.22% | -633.33% |
| Normalized Basic EPS | 81.58% | 78.08% | 73.02% | -525.00% | -500.00% |
| EPS Diluted | 82.08% | 78.70% | 73.27% | -642.22% | -633.33% |
| Normalized Diluted EPS | 81.58% | 78.08% | 73.02% | -525.00% | -500.00% |
| Average Basic Shares Outstanding | 0.12% | 0.18% | 0.25% | 0.19% | 0.25% |
| Average Diluted Shares Outstanding | 0.12% | 0.18% | 0.25% | 0.19% | 0.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |